Congress may give U.S. regulators greater oversight of pharmacy benefit managers amid Federal Trade Commission concern that these entities might be using anti-competitive business practices to inflate drug prices.

“When PBMs were first created, they were beneficial to the entire health care system. There was more than a dozen large PBMs across the country, all competing with each other to provide clear details about costs, fees, and rebates to pharmacies and patients,” said Rep. James Comer, R-Kentucky, and chair of the House Oversight and Accountability Committee.